GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 274 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 274 shares of the stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $66.60, for a total transaction of $18,248.40. Following the sale, the chief financial officer now owns 44,951 shares of the company’s stock, valued at approximately $2,993,736.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kevin Feeley also recently made the following trade(s):

• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The stock was sold at an average price of $33.33, for a total transaction of $29,830.35.
• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The stock was sold at an average price of $31.71, for a total transaction of $8,308.02.

GeneDx Stock Down 4.8 %

Shares of NASDAQ WGS opened at $77.74 on Friday. The company has a quick ratio of 2.22, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average price of $47.44 and a 200 day moving average price of $33.39. GeneDx Holdings Corp. has a 52 week low of $1.16 and a 52 week high of $89.11. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -25.00 and a beta of 2.32.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. During the same period last year, the firm posted ($0.82) EPS. The firm’s revenue for the quarter was up 44.3% on a year-over-year basis. Equities research analysts anticipate that GeneDx Holdings Corp. will post -0.75 EPS for the current fiscal year.

Institutional Investors Weigh In On GeneDx

A number of institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. purchased a new stake in GeneDx in the third quarter valued at approximately $604,000. Palumbo Wealth Management LLC purchased a new stake in GeneDx in the third quarter valued at approximately $287,000. Precision Wealth Strategies LLC purchased a new stake in GeneDx in the third quarter valued at approximately $364,000. Raymond James & Associates purchased a new stake in GeneDx in the third quarter valued at approximately $8,090,000. Finally, CWM LLC purchased a new stake in GeneDx in the third quarter valued at approximately $89,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on WGS. Wells Fargo & Company raised their target price on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday. The Goldman Sachs Group raised their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday. Craig Hallum raised their target price on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday. TD Cowen raised their price objective on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, BTIG Research raised their price objective on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.